Christine (Larson) Årdal’s Post

🔷When we think about inflation, we need to give credit to the pharmaceutical industry for displacing every other sector (hospital, ambulatory/physician, etc.,) as the fastest growing cost element of the US healthcare system....this year will not disappoint as a whopper of a year for upward cost pressure. 🔷And which drugs are the biggest contributors? Semaglutide was the top (GLP-1 - officially a T2 diabetes drug but often used for rapid weight loss) adalimumab (a.k.a. Humira and all it's biosimilar cousins) than apixaban (a.k.a. eloquis - an anticoagulant medication) #healthcare #inflation #drugcosts

"Beginning in 2005, lenalidomide's price was raised 22 times, from $215 USD per pill in 2005 to $719 USD, and then after Bristol Myers Squibb's acquisition of Celgene in 2019, lenalidomide's price increased to $763 USD per pill (Fig 1). By late 2020, a 1-month supply of branded lenalidomide was $16,023 USD, triple the 2005 price of $4,515 USD. Celgene's strategies effectively yielded $53 USD billion in net worldwide revenue between 2009 and 2018. US revenue comprised 63% of Celgene's total net revenue during that period." When the patent expired in Europe and Revlimid got generic competition in 2022, prices dropped substantially. A Dutch article states that the discount was over 99% and reports that a tablet that used to cost 218 euros in 2022 costs only 0.9 euros. I suppose it is up to you to decide whether these are clever strategies or pure greed, but greed is what this indicates to me. 

Codeine Market Outlook 2024-2030 For Additional Information, Get a Sample Copy>>> https://lnkd.in/dswaUvzu The codeine market refers to the segment of the pharmaceutical industry that focuses on the production, distribution, and sale of codeine, an opioid medication used primarily to treat mild to moderate pain, coughing, and diarrhea. As a controlled substance, codeine is often formulated in combination with other medications like acetaminophen or ibuprofen and is available in both prescription and over-the-counter products in some regions. The market includes pharmaceutical companies, healthcare providers, and regulatory bodies, with demand driven by the need for effective pain management and cough suppression. However, it is also regulated due to the potential for misuse and addiction. #KeyPlayers::: Alcaliber (Spain), AUROBINDO PHARMA LTD (India), Endo Pharmaceuticals (United States), GSK (United Kingdom), Johnson & Johnson (United States), Lannett Company, Inc. (United States), Lupin (India), Mallinckrodt Pharmaceuticals (United States), Noramco™ (United States), Rhodes Pharmaceuticals (United States), Sanofi (France), Sun Pharmaceutical Sdn Bhd (India) #CodeineMarket #Codeine #Pharmaceuticals #Pharmaceuticalindustry #pharmaceuticalnews #htfmi #htf HTF Market Intelligence Consulting Pvt Ltd

Choosing the right partner makes all the difference.

Transdermal Patches Market Worth $8.0 Billion Download a PDF Brochure: https://lnkd.in/dXq-94Nw The factors driving the growth of the global transdermal patches market include the rising prevalence of chronic diseases, the expanding use of analgesic patches, technological developments in transdermal patches, and the shift from traditional injections to transdermal patches. However, during the expected duration, factors such as medication failures, recalls of transdermal drug delivery systems, and escalating healthcare facility expenses are anticipated to limit the market's expansion to a certain degree. MYLAN N.V. Novartis Hisamitsu Pharmaceutical Co., Inc. Johnson & Johnson Limited, Janssen-Cilag Pharmaceuticals Bayer Consumer Care AG GSK Pfizer Inc. Luye Pharma Group Teva Pharmaceuticals Alvogen LEO Pharma Mundipharma Purdue Pharma L.P. Endo Pharmaceuticals UCB Noven Pharmaceuticals Pfizer Asahi Kasei #TransdermalPatches #DrugDeliveryPatches #SkinPatchMedication #PainReliefPatches #NicotinePatches #HormonalPatches #ControlledReleasePatch #NonInvasiveDrugDelivery #WearableMedication #TransdermalTherapeutics

Gemeinsamer Bundesausschuss (G-BA) Proposes Inclusion of Tapentadol in Fixed Price Group: Public Consultation Outcomes The Gemeinsamer Bundesausschuss (G-BA), Germany's top healthcare decision-making body, has proposed an amendment to the Drug Directive to include Tapentadol in the fixed price group system. This aims to ensure cost-efficiency in the public healthcare system. After extensive public consultation, which involved stakeholders like Grünenthal Group, a producer of Tapentadol, the Gemeinsamer Bundesausschuss (G-BA) decided that Tapentadol meets the criteria for inclusion. Despite concerns about European production costs and rebate contracts, the Gemeinsamer Bundesausschuss (G-BA) emphasized that the fixed price group would ensure affordable access to Tapentadol while maintaining therapeutic effectiveness, with implementation set for September 2024. For more details please click the link! https://lnkd.in/dhrhH2DS #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

José Luis Cárdenas Tomazic at Biosimilars LatAm - Colombia 2024, emphasized the importance of adopting a multi-criteria approach rather than solely focusing on price. This ensures that healthcare systems and patients receive the full value of #biosimilars, leading to sustainable supply and improved patient outcomes. Let's prioritize quality and accessibility in biosimilar procurement for a healthier future! Teva Pharmaceuticals IGBA - International Generic and Biosimilar medicines Association #BiosimilarsLatAm #HealthcareProcurement #PatientOutcomes

💊Acurx Pharmaceuticals' Ibezapolstat Shows Impressive Results!🌟 Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) compared top-line data from its breakthrough antibiotic, Ibezapolstat, against the current standard-of-care drugs on the market, and the results are highly promising! This could mark a significant advancement in treating bacterial infections. 🔬✨ Click the link for the full video👇🏻👇🏻👇🏻 https://lnkd.in/epRqi-Z9 #acurxpharmaceuticals #wellness #health #healthcare #cure #medicine #pharmacy #science #businessupdate #businessnews #business #news #newtothestreet

The US FDA has given the green light to adalimumab-ryvk (Simlandi), the first interchangeable, high-concentration, citrate-free adalimumab biosimilar. This marks a significant milestone as the 10th adalimumab biosimilar approved by the FDA and the inaugural approval for Alvotech, an Icelandic pharmaceutical company, in collaboration with Teva Pharmaceuticals. Robert Wessman, Chairman and CEO of Alvotech, highlighted the potential market impact of this interchangeable, citrate-free biosimilar in the evolving U.S. biosimilars environment. Adalimumab-ryvk, previously approved in the EU, Australia, and Canada, is indicated for various conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Notably, it is the third Humira biosimilar granted interchangeability status, allowing pharmacists (subject to state law) to substitute it for the reference product without involving the prescribing clinician. This distinguishes it from other biosimilars, which are only interchangeable with the low-concentration formulation of Humira. The imminent launch of Adalimumab-ryvk in the U.S. is eagerly awaited, with details on pricing yet to be disclosed. The biosimilar market continues to evolve, offering new options and potential cost savings for patients. Stay tuned for further updates! LINK:https://lnkd.in/eaxnuMdF #FDAApproval #Biosimilars #HealthcareInnovation

Let's talk #Stelara® (ustekinumab) for a moment. It will be the next higher-cost biological with biosimilars coming in 2025. And the next big one for self-funded plans to manage. If you're a plan fiduciary, you should be asking your #PBMs how they're going to handle it now in prep for the biosimilars coming in 2025. -According to the brand manufacturer's website, the list price of Stelara® is $25,497.12 every 8 weeks for the 90 mg dose as of March 2022. After initial doses and based upon the indication, it's used every 8 or 12 weeks. FDA Biosimilars thus far: 1. Wezlana (ustekinumab-auub) - The first Stelara biosimilar to be approved by the FDA, Wezlana is interchangeable with Stelara and is manufactured by Amgen.  2. Selarsdi (ustekinumab-aekn) - Developed and manufactured by Alvotech and Teva Pharmaceuticals, Selarsdi is approved for both adults and children. It is expected to be marketed in the US in February 2025.  3. Ustekinumab-ttwe - Sandoz will commercialize this biosimilar in the US, and it is expected to be one of the first to launch in the US. *Indications may vary Ask your PBMs: 1. If you have access to your data as a self-funded plan (you should, it's your data) - check and see if you have any on the plan now. If not, ask if there's any Stelara on the plan at present. 2. Which biosimilar will be on formulary? 3. By when? (Hint - the PBM should have it coming early in 2025.) 4. Will it be a high cost with drug rebates, or low cost without--or worst of both worlds, both, and then which one is the PBM choosing? (They'll probably be going high with drug rebates...) 5. If there are rebates, what will be coming back to the plan? 6. What will the members' copays be? 7. What will be the plan's cost? -Note: There is a high dose form of Stelara that hides out over in your medical benefits, because it is IV. Ask your PBM about that one too.... https://lnkd.in/geecGUnR Last, if you're a large employer with 1000+ employees, consider hiring a #pharmacist to manage your healthcare benefits plan and #prescriptiondrug spend. They are worth their weight in gold! #pharmacy